Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

Detalles Bibliográficos
Autores principales: Xu, Jianlin, Yang, Haitang, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Zhang, Xueyan, Zhong, Hua, Wang, Huiming, Wu, Dan, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Corrigenda
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131290/
https://www.ncbi.nlm.nih.gov/pubmed/27905549
http://dx.doi.org/10.1038/srep38270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131290/
https://www.ncbi.nlm.nih.gov/pubmed/27905549
http://dx.doi.org/10.1038/srep38270

Ejemplares similares